Section Arrow
Quote
MAZE.NASDAQ
- Maze Therapeutics Inc
Quotes are at least 15-min delayed:2026/06/23 06:50 EDT
Pre Market
Last
 26.11
+0.54 (+2.11%)
Bid
10.23
Ask
28.1
High 26.11 
Low 26.11 
Volume 25 
Regular Hours (Closed)
Last
 25.57
-0.11 (-0.43%)
Day High 
26.025 
Prev. Close
25.68 
1-M High
26.79 
Volume 
530.34K 
Bid
10.23
Ask
28.1
Day Low
25.34 
Open
25.69 
1-M Low
22.71 
Market Cap 
1.42B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 24.22 
20-SMA 24.95 
50-SMA 25.78 
52-W High 53.65 
52-W Low 9.83 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.35/-3.51
Enterprise Value
1.44B
Balance Sheet
Book Value Per Share
6.17
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
ADTXAditxt Inc.0.0192+0.0092+92.00%-- 
Pre Market 0.0257 +0.0065 +33.85%
AZTRAzitra0.23+0.0583+33.95%-- 
Pre Market 0.2 -0.03 -13.04%
CDTCDT Equity Inc.1.5+0.48+47.06%-- 
Pre Market 1.22 -0.28 -18.67%
APGEApogee Therapeutics132.55+42.17+46.66%-- 
Pre Market 132.4673 -0.0827 -0.06%
ENTXEntera Bio Ltd1.48+0.27+22.31%-- 
Pre Market 1.2684 -0.2116 -14.30%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM,diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.